Literature DB >> 23482742

Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma.

Sabine Mueller1, Samhita Bhargava, Annette M Molinaro, Xiaodong Yang, Ilan Kolkowitz, Aleksandra Olow, Noor Wehmeijer, Sharon Orbach, Justin Chen, Katherine K Matthay, Daphne A Haas-Kogan.   

Abstract

BACKGROUND/AIM: To assess poly (ADP-ribose) polymerase (PARP) inhibitor MK-4827 together with radiation for the treatment of neuroblastoma.
MATERIALS AND METHODS: Clonogenic survival assays were used to assess MK-4827, radiation and combination thereof in four neuroblastoma cell lines. In vivo efficacy was tested in a murine xenograft model of metastatic neuroblastoma. In vivo targeted inhibition and biological effects included measurement of cleaved caspase-3, γ-H2AX, and Ki 67 by immunohistochemistry (IHC) and poly-ADP-ribose by Enzyme-Linked Immunosorbent Assay.
RESULTS: Treatment of neuroblastoma cell lines reduced clonogenicity and resulted in additive effects with radiation. In vivo treatment with MK-4827 and radiation prolonged survival (p<0.01) compared to single modalities. In vivo superiority of MK-4827 plus radiation was further documented by significant elevations of cleaved caspase-3 and γ-H2AX in tumors from the combination group compared to single modality cohorts.
CONCLUSION: Combination of MK-4827 and radiation might provide effective therapy for children with high-risk neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23482742      PMCID: PMC3684561     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

1.  Clonogenic assay of cells in vitro.

Authors:  Nicolaas A P Franken; Hans M Rodermond; Jan Stap; Jaap Haveman; Chris van Bree
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.

Authors:  Sabine Mueller; Xiaodong Yang; Theo L Sottero; Ashley Gragg; Gautam Prasad; Mei-Yin Polley; William A Weiss; Katherine K Matthay; Andrew M Davidoff; Steven G DuBois; Daphne A Haas-Kogan
Journal:  Cancer Lett       Date:  2011-04-16       Impact factor: 8.679

3.  Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation.

Authors:  Jody Mitchell; Graeme C M Smith; Nicola J Curtin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-12-01       Impact factor: 7.038

4.  Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1.

Authors:  Valérie Schreiber; Jean-Christophe Amé; Pascal Dollé; Inès Schultz; Bruno Rinaldi; Valérie Fraulob; Josiane Ménissier-de Murcia; Gilbert de Murcia
Journal:  J Biol Chem       Date:  2002-04-10       Impact factor: 5.157

5.  Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.

Authors:  Denise Campisi Hegan; Yuhong Lu; Gregory C Stachelek; Meredith E Crosby; Ranjit S Bindra; Peter M Glazer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

6.  Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

Authors:  Rachel A Daniel; Agata L Rozanska; Huw D Thomas; Evan A Mulligan; Yvette Drew; Deborah J Castelbuono; Zdenek Hostomsky; E Ruth Plummer; Alan V Boddy; Deborah A Tweddle; Nicola J Curtin; Steven C Clifford
Journal:  Clin Cancer Res       Date:  2009-01-27       Impact factor: 12.531

7.  In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma.

Authors:  Paxton V Dickson; Blair Hamner; Catherine Y C Ng; Marshall M Hall; Junfang Zhou; Phillip W Hargrove; M Beth McCarville; Andrew M Davidoff
Journal:  J Pediatr Surg       Date:  2007-07       Impact factor: 2.545

8.  Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.

Authors:  Joana M Senra; Brian A Telfer; Kim E Cherry; Cian M McCrudden; David G Hirst; Mark J O'Connor; Stephen R Wedge; Ian J Stratford
Journal:  Mol Cancer Ther       Date:  2011-08-08       Impact factor: 6.261

9.  Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.

Authors:  E Dean; M R Middleton; T Pwint; H Swaisland; J Carmichael; P Goodege-Kunwar; M Ranson
Journal:  Br J Cancer       Date:  2012-01-05       Impact factor: 7.640

10.  Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells.

Authors:  Oliver Mortusewicz; Jean-Christophe Amé; Valérie Schreiber; Heinrich Leonhardt
Journal:  Nucleic Acids Res       Date:  2007-11-03       Impact factor: 16.971

View more
  12 in total

1.  Niraparib: First Global Approval.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

2.  Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.

Authors:  Anne L van de Ven; Shifalika Tangutoori; Paige Baldwin; Ju Qiao; Codi Gharagouzloo; Nina Seitzer; John G Clohessy; G Mike Makrigiorgos; Robert Cormack; Pier Paolo Pandolfi; Srinivas Sridhar
Journal:  Mol Cancer Ther       Date:  2017-05-12       Impact factor: 6.261

3.  PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

Authors:  V Colicchia; M Petroni; G Guarguaglini; F Sardina; M Sahún-Roncero; M Carbonari; B Ricci; C Heil; C Capalbo; F Belardinilli; A Coppa; G Peruzzi; I Screpanti; P Lavia; A Gulino; G Giannini
Journal:  Oncogene       Date:  2017-04-10       Impact factor: 9.867

4.  Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.

Authors:  Polly Gravells; James Neale; Emma Grant; Amit Nathubhai; Kate M Smith; Dominic I James; Helen E Bryant
Journal:  DNA Repair (Amst)       Date:  2017-11-22

5.  Molecular and functional analysis of anchorage independent, treatment-evasive neuroblastoma tumorspheres with enhanced malignant properties: A possible explanation for radio-therapy resistance.

Authors:  Tamara J Abou-Antoun; Javad Nazarian; Anthony Ghanem; Stanislav Vukmanovic; Anthony D Sandler
Journal:  PLoS One       Date:  2018-01-03       Impact factor: 3.240

6.  Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.

Authors:  Kathleen A Bridges; Carlo Toniatti; Carolyn A Buser; Huifeng Liu; Thomas A Buchholz; Raymond E Meyn
Journal:  Oncotarget       Date:  2014-07-15

Review 7.  Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.

Authors:  Keri A Streby; Nilay Shah; Mark A Ranalli; Anne Kunkler; Timothy P Cripe
Journal:  Pediatr Blood Cancer       Date:  2014-08-30       Impact factor: 3.167

8.  An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.

Authors:  Donna L Nile; Colin Rae; Iain J Hyndman; Mark N Gaze; Robert J Mairs
Journal:  BMC Cancer       Date:  2016-08-11       Impact factor: 4.430

Review 9.  PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.

Authors:  Mekonnen Sisay; Dumessa Edessa
Journal:  Gynecol Oncol Res Pract       Date:  2017-11-29

Review 10.  Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.

Authors:  Paul Lesueur; François Chevalier; Jean-Baptiste Austry; Waisse Waissi; Hélène Burckel; Georges Noël; Jean-Louis Habrand; Yannick Saintigny; Florence Joly
Journal:  Oncotarget       Date:  2017-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.